FUNDAMENTALS · Fundamentals · US Healthcare

Insight Molecular Diagnostics (IMDX) Fundamentals 2026 — Revenue Analysis | SniperIQ

Insight Molecular Diagnostics (IMDX) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of

36M, trading at $5.08 on the NASDAQ. This SniperIQ fundamentals page covers Insight Molecular Diagnostics's valuation, profitability (net margin -2454.6%), revenue ($4M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
36M
Net Margin-2454.6%
Revenue (FY25)$4M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Insight Molecular Diagnostics's market cap?

Insight Molecular Diagnostics (IMDX) has a market capitalization of approximately

36M, trading at $5.08 on the NASDAQ. Market cap moves with the live share price.

How profitable is Insight Molecular Diagnostics?

Insight Molecular Diagnostics runs a net profit margin of -2454.6%, a gross margin of 19.5%, and an operating margin of -2112.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Insight Molecular Diagnostics generate?

Insight Molecular Diagnostics reported revenue of $4M for fiscal year 2025, with net income of -$50M and earnings per share (EPS) of -1.65. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Insight Molecular Diagnostics pay a dividend?

Insight Molecular Diagnostics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Insight Molecular Diagnostics financially healthy?

Insight Molecular Diagnostics carries a debt-to-equity ratio of -0.29x and a current ratio of 2.54x, with a market beta of 1.76. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Insight Molecular Diagnostics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Insight Molecular Diagnostics (IMDX) the key facts are: market cap

36M, revenue $4M, 52-week range 2.33-8.51. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Insight Molecular Diagnostics's full fundamentals live

Get Insight Molecular Diagnostics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Vita Life Sciences (VLS) fundamentals · PepGen (PEPG) fundamentals · Pyxis Oncology (PYXS) fundamentals · Lana Medical (9587) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons